1 / 31

Welcome to SpA SIG

Welcome to SpA SIG. August 2, 2006. MR 304 : 15.30-16.30. How you diagnose and assess disease activity in AS: Results of a questionnaire study. Ratanavadee Nanagara, M.D. Allergy-Immunology-Rheumatology Unit KhonKaen University Thailand. Questionnaire.

ura
Download Presentation

Welcome to SpA SIG

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Welcome to SpA SIG August 2, 2006 MR 304 : 15.30-16.30

  2. How you diagnose and assess disease activity in AS: Results of a questionnaire study Ratanavadee Nanagara, M.D. Allergy-Immunology-Rheumatology Unit KhonKaen University Thailand

  3. Questionnaire parameters being used in common practice for diagnosis and assessment of AS patients. comments, suggestion, and revised by experience AS researchers 80 parameters for AS diagnosis, 32 for AS assessment electronically distributed

  4. Purpose to assess the degree of importance of …parameters used for diagnosis and assessment of AS patients … ….. up to the individual opinion.. used in clinical practice, not in research…. * each item was scored as 1 or 2 or 3. 1 = not important 2 = moderate important 3 = extremely important “The must” *** rheumatologist running clinical practice for at least 5-10 years

  5. 31 responders from 10 APLAR countries Hongkong (4) Isaac YIM, Cheuk-wan Lai Shan Tam Lau Chak Sing Lee Ka Wing Australia (1) Lionel Schachna Taiwan (1) Chung-Tei Chou Indonesia (1) John Darmawan Philippines (4) Evelyn Salido Juan Javier Lichauco Julie Li Yu Sandra V. Navarra Korea (3) Sang-Hoon, Lee. Tae-Hwan Kim Tae Jong Kim India (4) Ashok Kumar Rohini Handa Ved Chaturvedi Vikas Agarwal Thailand (4) Boonjing Siripaitoon Ratanavadee Nanagara Sittichai Ukritchon Worawit Laoraenu Results analysis Malaysia (4) Gun Suk Chyn Lew LWG Swan Sim Yeap Swee Gaik Ong Singapore (5) Anita Lim Chew Li-Ching Julian Thumboo Kok Ooi Kong Spore Bernard Thong

  6. > 80% of responders scored as important ( 2 + 3) Parameter for diagnosis 43 / 57 clinical parts 9 / 23 Lab. tests including: CRP, ESR, most plain films, and MRI 70% agree with B-27 study, less with RF Parameter for assessment 29 / 32 items listed Including: VAS, BASFI, BASDAI, GA, +BASMI

  7. > 80% of responders scored as “The Must” (3) Parameter for diagnosis Inflammatory back pain, morning pain, Schober test 433 / 57 clinical parts 9 1 / 23 Lab. tests film pelvis Parameter for assessment 291 / 32 items listed Schober test

  8. > 60% of responders scored as “The Must” (3) Parameter for diagnosis back pain characteristics eye sign, sausage digits chest expansion 43310 / 57 clinical parts 911 / 23 Lab. tests film pelvis 50% scored for MRI, 30% scored for B-27 Parameter for assessment Schober, morning pain peripheral joints & eye exam, VAS (pain, global), BASDAI, 291 6 / 32 items listed 50-60 % scored for chest expansion, enthesitis BASFI, CRP, ESR

  9. Conclusion (1) • Majority of the responders agree that most parameters used for diagnosis and assessment of AS patients are important. 2. However, limited numbers of these parameters have been using in their clinical practice. 3. At least, characteristics of back pain, Schober test, chest and eye exam, and film pelvis were evaluated by 80% of the responders.

  10. Conclusion (2) 4. About half used MRI of SI joint for AS diagnosis, while one third need genetic study. 5. Half of the responders used AS measurement parameters (BASDAI, BASFI, VAS) and inflammatory parameters (CRP, ESR) during AS assessment for their optimal care.

  11. 15:30-15:42How APLAR countries can contribute to international research David YU USA 15:42-15:54How you diagnose and assess disease activity in AS, results of a questionnaire study Ratanavadee Nanagara Thailand 15:54-16:06 Are UspA and AS 2 different diseases? Result from cohort study Chung-Tei Chou Taiwan 16:06-16:18Towards a perfect epidemiological Study of SpA, experience in China Swee Cheng Ng Singapore 16:18-16:30 Do UspA patients respond to TNF blockers Jieruo Gu China

  12. > 50% used in clinical practice

  13. > 70% > 50% used in clinical practice

  14. > 70% > 50% used in clinical practice

  15. > 70% > 50% used in clinical practice

  16. > 50% used in clinical practice

  17. > 70% > 50% used in clinical practice

  18. > 50% used in clinical practice

  19. > 50% used in clinical practice

  20. > 50% used in clinical practice > 70%

  21. > 50% used in clinical practice

  22. > 50% used in clinical practice

  23. > 50% used in clinical practice > 70%

  24. > 70% > 50% used in clinical practice

  25. > 70% > 50% used in clinical practice

More Related